Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Michael J. Fisher, Nicole J. Ullrich et al.|Neuro-Oncology|2014Cited by 147
Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemiaPatrick T. McGann, Alexander A. Vinks|American Journal of Hematology|2019Cited by 103
Sirolimus for non‐progressive NF1‐associated plexiform neurofibromas: An NF clinical trials consortium phase II studyBrian Weiss, Michael J. Fisher, Brigitte C. Widemann et al.|Pediatric Blood & Cancer|2013Cited by 87
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J. Ullrich, Mark W. Kieran, Sanjay P. Prabhu et al.|Neuro-Oncology|2020Cited by 82